Clinical Trial Update: Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating gefitinib for surgically resectable stage I–III esophageal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: University of Rochester | Conditions: Esophageal Cancer | Phase 2 | Status: TERMINATED